Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
- Revenue in USD (TTM)80.83k
- Net income in USD-28.86m
- Incorporated1987
- Employees--
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lyell Immunopharma Inc | 54.00k | -210.26m | 289.28m | 224.00 | -- | 0.5105 | -- | 5,357.10 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Personalis Inc | 80.03m | -81.45m | 289.72m | 223.00 | -- | 2.41 | -- | 3.62 | -1.63 | -1.63 | 1.59 | 2.12 | 0.3683 | 6.68 | 6.94 | 358,865.50 | -37.49 | -28.84 | -43.81 | -34.72 | 27.76 | 28.65 | -101.78 | -96.01 | 3.05 | -- | 0.0199 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Sutro Biopharma Inc | 169.36m | -124.45m | 290.97m | 304.00 | -- | 1.91 | -- | 1.72 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Tscan Therapeutics Inc | 12.20m | -104.41m | 291.36m | 175.00 | -- | 1.14 | -- | 23.88 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -123.44m | 295.80m | 33.00 | -- | 1.28 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Heron Therapeutics Inc | 136.36m | -48.13m | 297.27m | 126.00 | -- | -- | -- | 2.18 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Alto Neuroscience Inc | -100.00bn | -100.00bn | 297.63m | 78.00 | -- | 1.66 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
PepGen Inc | 0.00 | -89.14m | 305.04m | 64.00 | -- | 1.96 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 311.16m | 103.00 | -- | 1.38 | -- | 54.03 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Immutep Ltd - ADR | 80.83k | -28.86m | 311.29m | -- | -- | 2.35 | -- | 3,851.35 | -0.2382 | -0.2382 | 0.0007 | 0.8735 | 0.0007 | -- | 0.655 | -- | -24.48 | -- | -25.99 | -- | -- | -- | -35,710.27 | -- | -- | -- | 0.0083 | -- | -37.61 | -- | -7.07 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 313.75m | 10.00 | -- | 3.19 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
MeiraGTx Holdings PLC | 8.12m | -93.14m | 317.23m | 387.00 | -- | 3.32 | -- | 39.06 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
XOMA Royalty Corp | 15.24m | -25.10m | 320.82m | 13.00 | -- | 3.20 | -- | 21.05 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
ADC Therapeutics SA | 66.75m | -214.86m | 321.97m | 273.00 | -- | -- | -- | 4.82 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Inozyme Pharma Inc | 0.00 | -88.56m | 327.47m | 59.00 | -- | 3.43 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
GH Research PLC | -100.00bn | -100.00bn | 327.78m | 49.00 | -- | 1.65 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Pengana Capital Ltd.as of 28 Mar 2024 | 980.61k | 0.78% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 749.46k | 0.59% |
Oracle Investment Management, Inc.as of 31 Mar 2024 | 564.88k | 0.45% |
Meridian Wealth Management LLCas of 30 Jun 2024 | 381.20k | 0.30% |
Millennium Management LLCas of 31 Mar 2024 | 349.46k | 0.28% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 172.80k | 0.14% |
Caption Management LLCas of 31 Mar 2024 | 73.29k | 0.06% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 66.44k | 0.05% |
XY Capital Ltd.as of 30 Jun 2024 | 52.01k | 0.04% |
PFG Investments LLCas of 30 Jun 2024 | 51.00k | 0.04% |